secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2021-08-27T23:59:59+00:00
Accession:  0001193125-21-258064
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Teva appoints Dr. Tal Zaks to Board of Directors, effective Oct 1, 2021
-----------------------------------------------------------------------

- Dr. Tal Zaks elected to Teva Board, effective Oct 1, 2021, until 2022 annual meeting.
- Zaks joins from Moderna where he was Chief Medical Officer; departs late Sept 2021.
- Determined independent under NYSE rules; appointed to Science and Technology Committee.
- Will receive same compensation as other non-executive directors (see 2020 proxy).
- Zaks has MD/PhD, experience at Sanofi, Cephalon, GSK, and as adjunct professor at UPenn and Tufts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312521258064/0001193125-21-258064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312521258064/d224223d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-258064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer